Methods of preventing or treating neurogenic shock are provided. Accordingly there is provided a method of treating neurogenic shock following nerve injury in a subject comprising implanting a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant, at or near the nerve injury of the subject. Also provided is a method of preventing or treating neurogenic shock following nerve injury in a subject comprising implanting within 48 hours following the nerve injury a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant, at or near the nerve injury of the subject.

Methods of preventing or treating neurogenic shock are provided. Accordingly there is provided a method of treating neurogenic shock following nerve injury in a subject comprising implanting a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant, at or near the nerve injury of the subject. Also provided is a method of preventing or treating neurogenic shock following nerve injury in a subject comprising implanting within 48 hours following the nerve injury a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant, at or near the nerve injury of the subject.

Conformationally-stable peptide analogs of the response selective C5a agonist EP67 having the formula Tyr-Ser-Phe-Lys-Asp-Met-Xaa-(Xaa2)-(D-Ala)-Arg (SEQ ID NO:1), wherein Xaa is a modified proline residue or a residue substitution for proline, and Xaa2 is leucine or N-methyl leucine. The conformationally-stable peptides selectively bind and activate APCs without directly engaging/binding C5a receptor-bearing cells involved in pro-inflammatory activities of natural C5a. Compositions and methods of using the peptide analogs are also described.

The invention relates to a product suitable for the treatment of tear film deficiency in dry eye disease and a method for manufacturing the product. The invention also relates to a product for use in the treatment of tear film deficiency in dry eye disease. The product according to the invention provides for an improved wound healing in dry eye disease and other pathologies.